<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866539</url>
  </required_header>
  <id_info>
    <org_study_id>OI - 001 - 2016</org_study_id>
    <nct_id>NCT02866539</nct_id>
  </id_info>
  <brief_title>Effect of Polyherbal Compound for Control of Blood Sugar in Impaired Glucose Tolerance and Diabetes</brief_title>
  <official_title>A Polyherbal for Control of Blood Sugar in Subjects With Impaired Glucose Tolerance and/or Early Type 2 Diabetes. A Randomized Placebo Controlled Study of a Polyherbal (Whole Herb Formulation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organic India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Organic India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to control blood sugar with Sugar Balance capsules which is the
      leaves of three herbs: ivy ground (Coccinia indica)-200mg, bougainvillia (Bougainvillea
      spectabilis)-30mg, Madagascar periwinkle (Catharanthus rosea)-20mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">January 15, 2018</completion_date>
  <primary_completion_date type="Actual">December 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of diabetes subjects achieving glycemic control</measure>
    <time_frame>6 months</time_frame>
    <description>a 0.5% reduction in baseline A1c and/or fasting plasma glucose below 125 mg/dl or 2 hour postprandial glucose &lt;180 mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of pre-diabetes achieving euglycemic status</measure>
    <time_frame>6 months</time_frame>
    <description>measured as A1c &lt; 5.7% and/or fasting plasma glucose &lt;100mg/dl/</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Polyherbal capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will contain an inert substance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyherbal capsule coccinia, bougainvillea, catharanthus</intervention_name>
    <description>A unique combination of 3 herbs that lower blood sugars</description>
    <arm_group_label>Polyherbal capsule</arm_group_label>
    <other_name>Sugar Balance (SB)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar looking inactive powder</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males and non-pregnant females aged ≥30 years having a diagnosis of pre-diabetes
             (impaired fasting glucose or impaired glucose tolerance) and a diabetes and a meeting
             one of the following criteria

               1. Fasting Plasma Glucose ≥100 mg/dL, fasting is defined as no caloric intake for at
                  least 8 h, OR

               2. 2-h Post load Glucose ≥140 mg/dL during an Oral Glucose Tolerance Test (OGTT).
                  The test should be performed as described by the World Health Organisation(WHO),
                  using a glucose load containing the equivalent of 75 g anhydrous glucose
                  dissolved in water. OR

               3. Glycosylated haemoglobin (A1C) ≥5.7%. The test should be performed in a
                  laboratory using a method that is National Accreditation Board for Testing and
                  Calibration Laboratories certified and standardized. OR

               4. In a patient with classic symptoms of hyperglycaemia or hyperglycaemic crisis, a
                  random plasma glucose ≥200 mg/dL in the last 12 months.

        Exclusion Criteria:

          -  Any one of the following

               1. History of diabetes onset &gt;12 months from date of randomization and/or on any
                  oral hypoglycemic agents (other than metformin)

               2. Any history suggestive of micro vascular or macro vascular disease

               3. Women in childbearing age unable to practice any form of contraception

               4. Impaired renal function; estimated glomerular filtration rate(eGFR)
                  &lt;60mls/min/1.73m2.

               5. Known history of any chronic illness taking regular pharmacological agents.

               6. Blood pressure fluctuations exceeding 10 mmHg on 2 subsequent clinic visits or
                  known history of hypotension or bradycardia in last 6 months or taking 2 or more
                  antihypertensive medications regularly in the last 6 weeks

               7. Current or former employees of organic India

               8. Participating in another clinical trial with an active intervention or drug or
                  device with last dose taken within 60 days.

               9. Refusing consent or physician uncomfortable with patient compliance to treatments
                  or follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alben Sigamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Narayana Hrudayalaya Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Narayana Hrudayalaya Limited, Mazumdar Shaw multispecialty Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

